Knuff & Co LLC Sells 2,137 Shares of Danaher Corporation $DHR

Key Points

• Knuff & Co LLC has reduced its stake in Danaher Corporation by 25.4%, now owning 6,270 shares valued at approximately $1.29 million.
• Danaher reported strong quarterly earnings, with an EPS of $1.80 beating expectations by $0.16, and revenues of $5.94 billion, up 3.4% year-over-year.
• Despite several brokerages lowering their price targets, Danaher maintains a consensus rating of "Moderate Buy" with an average target price of approximately $247.61.

Knuff & Co LLC decreased its position in Danaher Corporation (NYSE:DHR - Free Report) by 25.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,270 shares of the conglomerate's stock after selling 2,137 shares during the period. Knuff & Co LLC's holdings in Danaher were worth $1,285,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Nuveen LLC acquired a new position in Danaher in the 1st quarter worth $833,941,000. GAMMA Investing LLC increased its position in Danaher by 24,958.2% during the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after acquiring an additional 1,863,381 shares during the period. Two Sigma Advisers LP raised its holdings in Danaher by 4,248.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock valued at $376,347,000 after acquiring an additional 1,601,800 shares in the last quarter. Capital World Investors increased its position in shares of Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock worth $1,460,215,000 after purchasing an additional 1,566,658 shares during the period. Finally, Invesco Ltd. boosted its stake in Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after buying an additional 1,450,703 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent research reports. TD Cowen lifted their price target on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research note on Friday, July 11th. Argus lowered their target price on shares of Danaher from $260.00 to $240.00 in a report on Wednesday, April 23rd. HSBC reduced their target price on shares of Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Seventeen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $247.61.

Danaher Price Performance

NYSE:DHR traded up $3.2250 during midday trading on Tuesday, hitting $212.2350. The company had a trading volume of 4,850,978 shares, compared to its average volume of 4,454,857. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $151.97 billion, a PE ratio of 45.16, a P/E/G ratio of 2.92 and a beta of 0.73. The stock's fifty day moving average price is $200.14 and its 200-day moving average price is $199.45. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company's revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.